These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7224)

  • 1. Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype.
    Hunyor SN
    Aust N Z J Med; 1975 Dec; 5(6):530-6. PubMed ID: 7224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrallazine with beta-blocker and diuretic in the treatment of hypertension. A double-blind crossover study.
    Kalowski S; Hua AS; Whitworth JA; Kincaid-Smith P
    Med J Aust; 1979 Oct; 2(8):439-40. PubMed ID: 318493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrallazine or phentolamine as adjuncts to beta-adrenoceptor blockade/thiazide therapy in hypertension.
    Winchester JF; Ward DM; McKillop JH; Kennedy AC
    Br J Clin Pharmacol; 1976 Oct; 3(5):863-7. PubMed ID: 788759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and cardiac haemodynamic interactions between guanfacine and hydrallazine in hypertensive patients.
    Velasco M; Urbina-Quintana A; Morillo J; Vizcarrondo H; Ramirez A; Hernández E; Hernández-Pieretti O
    Eur J Clin Pharmacol; 1984; 27(4):393-6. PubMed ID: 6394347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension.
    West MJ; Wing LM; Mulligan J; Walkley J; Grygiel JJ; Graham JR; Chalmers JP
    Med J Aust; 1980 Mar; 1(5):224-5. PubMed ID: 6990215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies with prazosin--a new effective hypotensive agent. III. An acute double-blind cross-over study comparing the effects of single doses of prazosin and hydrallazine in combination with propranolol and a diuretic.
    Hua AS; Myers JB; Kincaid-Smith P
    Med J Aust; 1978 Jan; 1(1):45-8. PubMed ID: 368538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
    Rashid JR; Kofi-Tsepko ; Juma FD
    East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propranolol and hydrallazine in the management of essential hypertension in pregnancy.
    Bott-Kanner G; Schweitzer A; Reisner SH; Joel-Cohen SJ; Rosenfeld JB
    Br J Obstet Gynaecol; 1980 Feb; 87(2):110-4. PubMed ID: 7362797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prazosin and hydrallazine in the treatment of hypertension.
    Kincaid-Smith P; Hua AS; Myers JB; MacDonald I; Fang P
    Clin Sci Mol Med Suppl; 1976 Dec; 3():617s-619s. PubMed ID: 1071692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxprenolol and hydrallazine in the treatment of hypertension.
    Freeman JW; Knight LW
    Med J Aust; 1975 Jan; 1(SP2):12-3. PubMed ID: 1124019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of once daily hydralazine in inadequately controlled hypertension.
    Danielson M; Kjellberg J; Ohman P; Wernersson B
    Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diuretics, beta blockers and vasodilators. Dosage in mild and moderate hypertension.
    Goble AJ
    Med J Aust; 1975 Jan; 1(SP2):14-7. PubMed ID: 1124020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrallazine and prazosin.
    Zacest R; Wilson CL
    Med J Aust; 1978 Apr; 1(8):443-4. PubMed ID: 26859
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sympathetic reflex responses during treatment of essential hypertension with hydrallazine and oxprenolol.
    Davies IB; Sever PS; Rosenthal T
    Br J Clin Pharmacol; 1979 Jul; 8(1):49-51. PubMed ID: 399592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension.
    Paran E; Holzberg G; Mazor M; Zmora E; Insler V
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):119-23. PubMed ID: 7757311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype.
    Harland SJ; Facchini V; Timbrell JA
    Br Med J; 1980 Jul; 281(6235):273-4. PubMed ID: 7427242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.